MEASLES, MUMPS AND RUBELLA VIRUS VACCINE

The single dose of vaccine in a lyophilized form contains atleast 1000 TCID 50 of live hyper-attenuated measles virus, strain Schwarz, prepared on primary chicken embryo cells, at least 5000 TCID 50 of live attenuated mumps virus, strain Urabe AM-9, prepared by culture in embryonated hen eggs, at least 1000 TCID 50 of live attenuated rubella, strain Wistar RA 27/3M, cultured on human diploid cells. Stabilizer, human placental albumin:q.s for lyophilisation. Diluent: water for injection 0.5 ml.

Indications

Joint prevention of measles, mumps and rubella, normally, given from the age of 12 months, in infants of both sexes. In infants living in community, this age limit is brought down to 9 months.

Dosage

Subcutaneous or intramuscular route. Combined vaccination only entails a single injection recommended between 12 and 15 months of age. Nevertheless , in infants vaccinated below the age of 1 year, specially for those living community, a second injection 6 months later is recommended.

Contra-Indications

Congenital or acquired immune deficiency. True allergy to egg proteins (anaphylactic reaction after ingestion of eggs). Recent injection of immune globulins.

Special Precautions

The rubella vaccination of post-pubertal woman will be made only if the woman is not pregnant at that time of the injection, neither the following two months after the vaccination.

Side Effects

Hyperthermia (which can be prevented with a antipyretic), rhinopharyngeal or respiratory symptoms of short duration, discreet exanthema. Hyperthermia convulsions are rarely observed. Lymphadenopathies or parotitis may be observed.